

Rong-Fu Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6622900/publications.pdf>

Version: 2024-02-01

45
papers

5,216
citations

117625

34
h-index

243625

44
g-index

45
all docs

45
docs citations

45
times ranked

7752
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. <i>Journal of Neuroinflammation</i> , 2019, 16, 53.	7.2	446
2	NLRC5 Negatively Regulates the NF- κ B and Type I Interferon Signaling Pathways. <i>Cell</i> , 2010, 141, 483-496.	28.9	365
3	Cancer therapy using a self-replicating RNA vaccine. <i>Nature Medicine</i> , 1999, 5, 823-827.	30.7	311
4	TRIM14 Inhibits cGAS Degradation Mediated by Selective Autophagy Receptor p62 to Promote Innate Immune Responses. <i>Molecular Cell</i> , 2016, 64, 105-119.	9.7	277
5	Human tumor antigens for cancer vaccine development. <i>Immunological Reviews</i> , 1999, 170, 85-100.	6.0	268
6	Mechanisms and pathways of innate immune activation and regulation in health and cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3270-3285.	3.3	246
7	NLRX1 Negatively Regulates TLR-Induced NF- κ B Signaling by Targeting TRAF6 and IKK. <i>Immunity</i> , 2011, 34, 843-853.	14.3	241
8	NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4. <i>Nature Immunology</i> , 2012, 13, 387-395.	14.5	229
9	Immune targets and neoantigens for cancer immunotherapy and precision medicine. <i>Cell Research</i> , 2017, 27, 11-37.	12.0	185
10	Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity. <i>Frontiers in Immunology</i> , 2022, 13, 812774.	4.8	157
11	Jmjd3 Inhibits Reprogramming by Upregulating Expression of INK4a/Arf and Targeting PHF20 for Ubiquitination. <i>Cell</i> , 2013, 152, 1037-1050.	28.9	147
12	TRIM11 Suppresses AIM2 Inflammasome by Degrading AIM2 via p62-Dependent Selective Autophagy. <i>Cell Reports</i> , 2016, 16, 1988-2002.	6.4	141
13	Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation. <i>Nature Communications</i> , 2014, 5, 5780.	12.8	136
14	USP19 modulates autophagy and antiviral immune responses by deubiquitinating Beclin1. <i>EMBO Journal</i> , 2016, 35, 866-880.	7.8	136
15	Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules. <i>Journal of Immunology</i> , 2000, 165, 1153-1159.	0.8	130
16	Identification of a Novel Major Histocompatibility Complex Class II-restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells. <i>Journal of Experimental Medicine</i> , 1999, 189, 1659-1668.	8.5	126
17	LRRC25 inhibits type I IFN signaling by targeting ISG15-associated RIGI for autophagic degradation. <i>EMBO Journal</i> , 2018, 37, 351-366.	7.8	123
18	Current advances in T-cell-based cancer immunotherapy. <i>Immunotherapy</i> , 2014, 6, 1265-1278.	2.0	119

#	ARTICLE	IF	CITATIONS
19	JMJD3 as an epigenetic regulator in development and disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 67, 148-157.	2.8	111
20	Enhanced TLR-induced NF- κ B signaling and type I interferon responses in NLRC5 deficient mice. <i>Cell Research</i> , 2012, 22, 822-835.	12.0	110
21	USP38 Inhibits Type I Interferon Signaling by Editing TBK1 Ubiquitination through NLRP4 Signalosome. <i>Molecular Cell</i> , 2016, 64, 267-281.	9.7	107
22	Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality. <i>Immunity</i> , 2016, 45, 1093-1107.	14.3	100
23	Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. <i>Cancer Research</i> , 2002, 62, 3630-5.	0.9	89
24	USP18 negatively regulates NF- κ B signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms. <i>Scientific Reports</i> , 2015, 5, 12738.	3.3	86
25	Assembly of the WHIP-TRIM14-PPP6C Mitochondrial Complex Promotes RIG-I-Mediated Antiviral Signaling. <i>Molecular Cell</i> , 2017, 68, 293-307.e5.	9.7	77
26	Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. <i>Nature Metabolism</i> , 2021, 3, 1466-1475.	11.9	76
27	Strain-specific innate immune signaling pathways determine malaria parasitemia dynamics and host mortality. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E511-20.	7.1	74
28	Microbiota regulate innate immune signaling and protective immunity against cancer. <i>Cell Host and Microbe</i> , 2021, 29, 959-974.e7.	11.0	67
29	Targeting epigenetic regulations in cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 97-109.	2.0	60
30	Cell-Penetrating Nanoparticles Activate the Inflammasome to Enhance Antibody Production by Targeting Microtubule-Associated Protein 1-Light Chain 3 for Degradation. <i>ACS Nano</i> , 2020, 14, 3703-3717.	14.6	55
31	Stage-Dependent and Locus-Specific Role of Histone Demethylase Jumonji D3 (JMJD3) in the Embryonic Stages of Lung Development. <i>PLoS Genetics</i> , 2014, 10, e1004524.	3.5	50
32	Evaluation of Single-Cell Cytokine Secretion and Cell-Cell Interactions with a Hierarchical Loading Microwell Chip. <i>Cell Reports</i> , 2020, 31, 107574.	6.4	50
33	Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. <i>Journal of Leukocyte Biology</i> , 1996, 60, 296-309.	3.3	43
34	Reversible ubiquitination shapes NLRC5 function and modulates NF- κ B activation switch. <i>Journal of Cell Biology</i> , 2015, 211, 1025-1040.	5.2	43
35	FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions. <i>MBio</i> , 2017, 8, .	4.1	38
36	Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice. <i>European Heart Journal</i> , 2021, 42, 4352-4369.	2.2	38

#	ARTICLE	IF	CITATIONS
37	A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 689-696.	7.0	38
38	RTP4 inhibits IFN-I response and enhances experimental cerebral malaria and neuropathology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 19465-19474.	7.1	31
39	HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2014, 32, 235-242.	2.6	21
40	Genome-wide Analysis of Host-Plasmodium yoelii Interactions Reveals Regulators of the Type I Interferon Response. <i>Cell Reports</i> , 2015, 12, 661-672.	6.4	21
41	Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. , 2022, 10, e004035.		17
42	Activation of cGAS–STING by Lethal Malaria N67C Dictates Immunity and Mortality through Induction of CD11b ⁺ Ly6C ^{hi} Proinflammatory Monocytes. <i>Advanced Science</i> , 2022, 9, .	11.2	11
43	Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells. <i>PLoS ONE</i> , 2015, 10, e0124094.	2.5	9
44	BECN2 (beclin 2)-mediated non-canonical autophagy in innate immune signaling and tumor development. <i>Autophagy</i> , 2020, 16, 2310-2312.	9.1	6
45	Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. <i>Oncotarget</i> , 2021, 12, 2449-2458.	1.8	5